Who you are

Life Sciences & Pharma

Where does your molecule, process or formulation actually stand?

India's pharma sector is where patent law is argued hardest — Section 3(d), compulsory licensing, and a body of case law that decides what is patentable here rather than elsewhere. The work is landscaping before you spend, and knowing which side of the line your claim falls on.

Why businesses like yours call us

  • Section 3(d) sits between you and a grant — incremental innovation is judged differently in India
  • The register is crowded — landscaping before R&D spend, not after
  • Licensing and technology transfer — the deal depends on rights clean enough to rely on

Where to start

  • Entry product — Competitor IP Snapshot
  • One firm throughout — you are not handed to another firm at the next rung.
Fee — scoped to your business, quoted in writing before you commit. No rate card, no hourly meter: the number you agree to is the number you pay.
Book a discovery call See how we price
The work

The rungs that matter most here.

The ladder is the same for everyone. These are the steps this situation usually starts on.

RungLandscapingRungPortfolio StrategyRungCommercialization & Licensing
Questions people ask

The things clients ask in this position.

Can I patent an app or software in India? Can I patent something I have already shown publicly? How long does a patent last in India? How do I license my IP and earn from it?
How it played out

Cases worth reading first.

Public IP disputes, read for what they teach. These are not our clients — they are the record.

Novartis v Union of India — Section 3(d) and What Is Patentable in India Bayer v Natco (Nexavar) — India's First Compulsory Licence Roche v Cipla (Erlotinib) — India's First Major Pharma Patent Trial Turmeric Patent Revocation — How India Used Prior Art to Win